These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27432932)

  • 1. Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
    Strulov Shachar S; Hurria A; Muss HB
    J Clin Oncol; 2016 Oct; 34(28):3486-8. PubMed ID: 27432932
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives.
    Soto-Perez-De-Celis E; Loh KP; Baldini C; Battisti NML; Chavarri-Guerra Y; De Glas NA; Hsu T; Hurria A
    Expert Opin Investig Drugs; 2018 Oct; 27(10):787-801. PubMed ID: 30196727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 5. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
    Florido R; Smith KL; Cuomo KK; Russell SD
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel targeted agents for the treatment of advanced breast cancer.
    de la Vega M; Díaz-Cantón E; Alvarez RH
    Future Med Chem; 2012 May; 4(7):893-914. PubMed ID: 22571614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the androgen receptor in breast cancer.
    Chia K; O'Brien M; Brown M; Lim E
    Curr Oncol Rep; 2015 Feb; 17(2):4. PubMed ID: 25665553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in the treatment of breast cancer and localized sarcomas.
    Lumachi F
    Curr Med Chem; 2013; 20(5):593-5. PubMed ID: 23278397
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer targeted therapy: successes and challenges.
    The Lancet
    Lancet; 2017 Jun; 389(10087):2350. PubMed ID: 28635596
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone-Targeted Therapy in Early Breast Cancer.
    Jerzak KJ; Raphael J; Desautels DN; Blanchette PS; Tyono I; Pritchard KI
    Oncology (Williston Park); 2018 Nov; 32(11):562-9. PubMed ID: 30474104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Locally advanced breast cancer (methods of treatment)].
    Portnoĭ SM
    Vopr Onkol; 2011; 57(5):553-8. PubMed ID: 22238923
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design.
    Alvarez RH; Hortobagyi GN
    Breast Cancer Res Treat; 2010 Dec; 124(3):701-5. PubMed ID: 20953832
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials. Experimental cancer therapies move to the front line.
    Couzin-Frankel J
    Science; 2012 Jan; 335(6066):282-3. PubMed ID: 22267789
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice-changing data in metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2013; 11(10 Suppl 16):7-12. PubMed ID: 24637555
    [No Abstract]   [Full Text] [Related]  

  • 18. Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.
    Neal JW; Sledge GW
    Nat Rev Clin Oncol; 2014 Nov; 11(11):627-8. PubMed ID: 25286974
    [No Abstract]   [Full Text] [Related]  

  • 19. [Her2 positive breast cancer: practices].
    Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
    Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drugs in oncology: benefits, risks and challenges].
    Cella D; Vervölgyi V; Wörmann B
    Onkologie; 2013; 36 Suppl 5():12-9. PubMed ID: 23921801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.